VERDOT® to Build New 4,200 Square-Meter Headquarters and Manufacturing Facility in Riom, France

23 September 2024 | Monday | News

The state-of-the-art facility will boost manufacturing capacity by 150%, consolidate existing operations, and create 50-75 new jobs, set to open in early 2026.

  • 4200 square-meter headquarter and manufacturing facility in Riom, France
  • Consolidation of existing facilities with 150% additional manufacturing capacity
  • Facility will be operational by early 2026

 

VERDOT®  announced that it has completed a transaction to purchase 11,000 square-meters (2.7 acres) of land in the Biopole Clermont-Limagne Life Science Technology Park in Riom, France, which is planned to be the site of an approximately 4200 square-meter (45,000 square-feet) headquarters and manufacturing facility. Construction is expected to begin in the first quarter of 2025.
 
The new site is anticipated to open early 2026. It will consolidate their existing two facilities, create a Center of Excellence for bioprocessing manufacturing, research and development, and an applications laboratory. The Company expects that the new facility will result in the creation of approximately 50-75 new jobs in the local area. 
 
The state-of-the-art facility will utilize the latest technologies to design, fabricate and assemble bioprocessing purification solutions as well as create 150% additional manufacturing capacity for the company.
 
The new manufacturing site will be energy efficient, self-sufficient in electricity generation, equipped with water collection and recycling systems, and compliant with all environmental and regulatory standards. This new site will contribute to continuing the ambitious company’s decarbonization trajectory, initiated over 10 years ago.
 
Charles Ruban, CEO of VERDOT commented, “We are excited to begin construction of our new facility. The new VERDOT facility will add significant manufacturing capacity, allowing us to further reduce lead times for tailored and standard purification technologies to meet the growing demand of our biopharmaceutical customers worldwide. The consolidation of our existing facilities will create operational and R&D efficiencies that will enhance our engineering capabilities and fuel innovation, while further reducing our carbon footprint.” 

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close